Respiri and Pharmacy Catalyst to begin wheezo in-pharmacy asthma patient program next month
The in-pharmacy program will be rolled-out across all Pharmacy Catalyst’s members throughout 2021.
Respiratory health focused Respiri (ASX: RSH) has bedded-in support for its wheezo device and technology after Pharmacy Platform member Pharmacy Catalyst confirmed it will begin the wheezo in-pharmacy asthma patient program next month.
Pharmacy Catalyst offers its 350 members professional service and education programs and is committed to community engagement with a patient-centric focus.
Under the agreement inked in December last year, Pharmacy Catalyst will stock and sell Respiri’s wheezo range for its in-pharmacy asthma patient program next month.
The program will see pharmacists working with asthma patients to review their conditions and make recommendations including the use of the wheezo device and app to improve asthma management.
Supporting the in-pharmacy patient program are Respiri’s partner Cipla and the Respiri Connect Care nursing team.
Roll-out of wheezo in 2021
Throughout the remainder of 2021, the program will be rolled-out across member pharmacies with white label options also available to other major pharmacy groups where active relationships exist with Pharmacy Catalyst.
Respiri chief executive officer and managing director Marjan Mikel said the Respiri team was “looking forward” to working with Pharmacy Catalyst members to roll-out programs that assist with patient engagement and education.
“Having Pharmacy Catalyst with its focus on individualised patient support is terrific for asthma patients and their care givers, and with wheezo now available, patients and care givers can benefit from improved asthma management.”
Meanwhile, Pharmacy Platform director Michael Flannery said its pharmacy members will be able to provide “much needed support” to asthma patients and their care givers to improve disease management and outcomes.
More pharmacy banner groups onboard
Respiri has now onboarded three pharmacy banner groups since the December quarter of last year.
In addition to the banner groups, the company has also onboarded several independent stores during the period.
All-up, Respiri’s wheezo technology is now within 500 pharmacies across Australia – amounting to a market penetration of about 10%.
Respiri is also in active discussions with other pharmacy banner groups which possess a footprint of more than 1,000 Australian stores.